SACD19-101 is under clinical development by Sian Wuhan Medical Technology and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III drugs for Follicular Lymphoma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SACD19-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SACD19-101 overview

SACD19-101 is under development for the treatment of relapsed or refractory CD19 positive B cell malignancies including indolent B-cell lymphoma such as  B-cell acute lymphocytic leukemia (B-cell acute lymphoblastic leukemia), follicular lymphoma, aggressive B-cell lymphoma such as diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma. It is administered as an infusion. The therapeutic candidate constitutes lentivirally transduced autologous CAR T cells genetically modified to target CD19. It was also under development for the treatment of marginal zone B-cell lymphoma, waldenstrom macroglobulinemia, B-cell acute lymphocytic leukemia,  lymphoplasmacytic lymphoma and chronic lymphocytic leukemia.

For a complete picture of SACD19-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.